Prosecution Insights
Last updated: November 08, 2026
Application No. 18/401,045

DEVICES AND METHODS FOR DELIVERING SYNERGISTIC ACTIVE AGENTS TO TARGET SITES

Non-Final OA §103§112§DP
Filed
Dec 29, 2023
Examiner
WRUBLESKI, MATTHEW JAMES
Art Unit
3781
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Irrimax Corporation
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
70 granted / 118 resolved
-10.7% vs TC avg
Strong +60% interview lift
Without
With
+60.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
49 currently pending
Career history
179
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
56.8%
+16.8% vs TC avg
§102
20.2%
-19.8% vs TC avg
§112
16.0%
-24.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 118 resolved cases

Office Action

§103 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 10 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 10, the claim fails to comply with the written description requirement as the claim requires comparison to an unknown “analogous method”. The analogous method is not defined and thus the claim is indefinite as one having ordinary skill could not reasonably determine what a specific analogous method would be in view of the claims. As best understood by the examiner one of the alternative methods (see para. 022 of the instant application) is merely saline, and thus it is interpreted that a specifically antibacterial solution would reasonably produce effects faster than a saline solution. However, this is not the only solution compared by the specification as the same citation also lists a solution containing only benzalkonium and no other ingredient. Thus, it is unclear how the comparison between different solutions and the claims are being made and how the applicant arrived at the specific pacing and/or reduction percentage. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 10, the claim is indefinite as the claim requires comparison to an unknown “analogous method”. The analogous method is not defined and thus the claim is indefinite as one having ordinary skill could not reasonably determine what a specific analogous method would be in view of the claims. As best understood by the examiner the alternative method (see para. 022 of the instant application) is merely saline, and thus it is interpreted that a specifically antibacterial solution would reasonably produce effects faster than a saline solution. However, this is not the only solution compared by the specification as the same citation also lists a solution containing only benzalkonium and no other ingredient. The claim is unclear as to what alternative solution is being compared to the claimed solution. The examiner notes that, for purpose of examination, a solution with the same ingredients with the same concentrations as claimed compared to the same analogous method as claimed would read to the claimed invention. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Rucinski US 7662125, provided in the IDS, in view of Wang et al. CN 108929247, hereafter Wang and as evidenced by Azeem, T. (2025, August 12). Chlorhexidine Gluconate 0.12%: A Clinical Guide. SurgiMac Dental Supply. https://surgimac.com/blogs/product-news/chlorhexidine-gluconate-012-vs-12mgml, hereafter SurgiMac. . Regarding claim 1 Rucinski discloses a method for irrigating a wound (abstract) comprising the steps of: (a) providing a non-sterile or sterile wound irrigation solution in a wound irrigation device comprising a .0004reservoir housing (see claim 1 of Rucinski, column 6 lines 36-41), wherein the wound irrigation device comprises a discharge means that directs a pressurized stream of the wound irrigation solution when the reservoir housing is pressurized (see claim 1, column 9, lines 20-48), and wherein the wound irrigation solution comprises (i) sterile water, purified water, or water for pharmaceutical purposes (claim 1, column 5 lines 10-15); (ii) a chlorhexidine at a concentration that is between about 100 μg /mL to about 5 mg/mL (claim 1, column 5 lines 10-15); and (iii) a benzalkonium salt (where antiseptic agents are commonly used in said solutions, where benzalkonium salt is a known ingredient per column 6 lines 47-67, specifically 65-67). The examiner notes that while a specific mg/mL ratio is not provided for the chlorohexidine, column 7 lines 63-67 and column 4 lines 1-9 detail that preferably the chlorohexidine solution is between .02 and 4%. The examiner notes that SurgiMac was used as an evidentiary reference to show the conversion factor for chlorohexidine. In this NPL the breakdown exhibits that .12% (the standard dosage) equates to .12g per 100mL of solution (see page 2). In simple balancing conversions .12g/100mL converts to .0012g/1mL and further to 1.2g/mL. Thus, a concentration of .02% would equate to .02g/100mL -> .0002gg/mL -> .2mg/mL (200µg/mL). Doing the same to 4% would equate to 40mg/mL. Thus, the range for mg/mL disclosed by Rucinski is 200µg/mL-40mg/mL and is thus overlapping with the claimed range. The examiner notes however, that no concentration of the benzalkonium salt is disclosed. In the citation of Rucinski, benzalkonium Salt is a cationic surface-active agent. Wang teaches antimicrobial compositions and is thus considered analogous to the claimed invention. Wang teaches that benzalkonium chloride was used as a cationic surfactants in the composition, where the concentrations ranged from 32μg/mL (para. 0081) to 64μg/mL (para. 0082) depending on what the solution was treating. Per the same citations, benzalkonium chloride was used with chlorhexidine. Therefore, as Benzalkonium chloride may have suitable concentrations of 32 and 64μg/mL in antimicrobial concentrations, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to provide the antimicrobial composition of Rucinski, comprising benzalkonium chloride, with a concentration 32μg/mL or 64 μg/mL, as said concentrations are known to be suitable in the art. As said value is within the claimed range, the prior art reads to the claimed invention. Rucinski further discloses directing the discharge means and the reservoir housing so as to discharge the wound irrigation solution toward the wound (claim 1, see also column 4 , lines 11-17); and (c) discharging a stream of the wound irrigation solution from the reservoir housing and through the discharge means directed at the wound (claim 1, see also column4 , lines 11-17). Regarding Claim 2, Rucinski and Wang teach the method of claim 1, wherein the wound irrigation solution consists of (i) sterile water, purified water, or water for pharmaceutical purposes (column 5 lines 10 of Rucinski); (ii) the chlorhexidine at a concentration that is between about 100 μg/mL to about 5 mg/mL (see rejection of claim 1, where 200μg/mL-40mg/mL was used); and (iii) the benzalkonium salt at a concentration that is between about 10 μg/mL to about 500 μg/mL (see rejection of claim 1 where 32μg/mL was found to be suitable). Regarding Claim 3, Rucinski and Wang teach the method of claim 1, wherein the chlorhexidine is in the form of chlorhexidine gluconate (see claim 8, column 8 lines 7-9). Regarding Claim 4, Rucinski and Wang teach the method of claim 1, wherein the concentration of the chlorhexidine is between about 200 μg/mL to about 1 mg/mL or about 100 μg/mL to about 500 μg/mL (see rejection of claim 1 where the prior art disclosed range of 200μg/mL-40mg/mL overlaps with the claimed range and thus reads to the claimed invention). Regarding Claim 5, Rucinski and Wang teach the method of claim 1, wherein the concentration of the chlorhexidine is about 500 μg/mL. The examiner notes that as detailed under the rejection of claim 1, the prior art range for concentration of chlorhexidine was found to be 200μg/mL-40mg/mL, thus about 500μg/mL. Regarding Claim 6, Rucinski and Wang teach the method of claim 1, wherein the benzalkonium salt is benzalkonium chloride (Rucinski column 6 lines 66-67). Regarding Claim 7, Rucinski and Wang teach the method of claim 1, wherein the concentration of the benzalkonium salt is between about 30 μg/mL to about 200 μg/mL. Per the rejection of claim 1, the concentration of benzalkonium salt (32μg/mL) is within the claimed range and thus reads to the claimed device. Regarding Claim 8, Rucinski and Wang teach the method of claim 1, wherein the concentration of the benzalkonium salt is between about 30 μg/mL to about 90 μg/mL or about 60 μg/mL to about 180 μg/mL. Per the rejection of claim 1, the concentration of benzalkonium salt (32 or 64 μg/mL) is within the claimed range and thus reads to the claimed device. Regarding Claim 9, Rucinski and Wang teach the method of claim 1, wherein the concentration of the benzalkonium salt is about 60 μg/mL or about 120 μg/mL. Per the rejection of claim 1, the concentration of benzalkonium salt (64μg/mL) is within the claimed range and thus reads to the claimed device. Regarding Claim 10, Rucinski and Wang teach the method of claim 1, wherein an amount of irrigation time required to reduce a bacterial burden of the wound or a fungal burden of the wound by about 100-fold compared to an analogous method using an alternative irrigation solution comprising the same concentration of chlorhexidine without an additional antiseptic agent is reduced by about 50%. The examiner notes that per the rejection of claim 1, the method of Rucinski, uses the same materials, found to be obvious to use in the same amounts as claimed, for the same application, and achieves the same results. Therefore, although no specific disclosure is had that the device of Rucinski is 50% faster than other solutions, due to the solutions of the prior art and the instant application being the same in view of the rejection of claim 1, the same results would be found in the prior art device. Regarding Claim 11, Rucinski and Wang teach the method of claim 1, wherein the irrigation solution comprises a combination of the chlorhexidine and the benzalkonium salt that is synergistically microbiocidal or microbiostatic to a fungus or a bacterium (column 7, lines 8-20). Regarding Claim 12, Rucinski and Wang teach the method of claim 11, wherein the fungus or the bacterium is selected from Candida species, E. coli, Staphylococcus species, Ralstonia species, Pseudomonas species, or a combination thereof (column 7 line 47, see also column 7, lines 28-36). Regarding Claim 13, Rucinski and Wang teach the method of claim 11, wherein the fungus or the bacterium is selected from E. coli, P. aeruginosa, or a combination thereof (column 7 line 37-40, where the treatment is active against Enterococcus). Regarding Claim 14, Rucinski and Wang teach the method of claim 10, wherein the amount of irrigation time required is within 15 minutes (column 8, lines 16-24, see also claim 5). Regarding Claim 15, Rucinski and Wang teach the method of claim 1, wherein about 10 ml to about 1000 ml of wound irrigation solution is applied to the wound (see claim 3, see also column 10 lines 25-28, where the volume of the container is 100-1000mL). Regarding Claim 16, Rucinski and Wang teach the method of claim 1, wherein the pH of the wound irrigation solution is between pH 5.5 and pH 7.0 (see column 5 lines 54-56, see also claim 9). Regarding Claim 17, Rucinski and Wang teach the method of claim 1, used to kill a microorganism selected from the group consisting of Candida species, E. coli, Staphylococcus species, Ralstonia species, Pseudomonas species, and a combination thereof (column 7, lines 28-36). Regarding Claim 18, Rucinski and Wang teach the method of claim 1, used to kill C. albicans, E. coli, methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Staphylococcus epidermidis, Ralstonia pickettii, P. aeruginosa, or a combination thereof (column 7 lines 34-35). Regarding Claim 19, Rucinski and Wang teach the method of claim 1, wherein the wound is a human skin wound and the method is used to treat the human skin wound (column 5, lines 12-15, see also claim 6). Regarding Claim 20, Rucinski and Wang teach the method of claim 1, wherein the wound is selected from the group consisting of cuts, scrapes, surgical wounds, punctures, and abrasions (Column 13, lines 1-3, see also claim 17). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-32 of U.S. Patent No. 7662125, hereafter 125’, in view of Wang. Regarding claim 1, see claim 1 of 125’. The examiner notes that two differences exist in the claims. 1) the concentration and use of benzalkonium salt, and 2) the concentration of chlorhexidine. Regarding 1, Wang teaches antimicrobial compositions and is thus considered analogous to the claimed invention. Wang teaches that benzalkonium chloride was used as a cationic surfactants in the composition, where the concentrations ranged from 32μg/mL (para. 0081) to 64μg/mL (para. 0082) depending on what the solution was treating. Per the same citations, benzalkonium chloride was used with chlorhexidine. Therefore, as Benzalkonium chloride may have suitable concentrations of 32 and 64μg/mL in antimicrobial concentrations, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to provide the antimicrobial composition of Rucinski, comprising benzalkonium chloride, with a concentration 32μg/mL or 64 μg/mL, as said concentrations are known to be suitable in the art. As said value is within the claimed range, the prior art reads to the claimed invention. Regarding claim 2, see rejection of claim 1 under double patenting above, and claim 1 of 125’. Regarding claim 3, see rejection of claim 1 under double patenting above, and claim 8 of 125’. Regarding claim 4, see rejection of claim 1 under double patenting above, and claim 1 of 125’. Regarding claim 5, see rejection of claim 1 under double patenting above, and claim 1 of 125’. Regarding claim 6, see rejection of claim 1 under double patenting above, and claim 1 of 125’. Regarding claim 7, see rejection of claim 1 under double patenting above, and claim 1 of 125’. Regarding claim 8, see rejection of claim 1 under double patenting above, and claim 1 of 125’. Regarding claim 9, see rejection of claim 1 under double patenting above, and claim 1 of 125’. Regarding claim 10, see rejection of claim 1 under double patenting above, and claim 1 of 125’. Regarding claim 11, see rejection of claim 16 under double patenting above, and claim 1 of 125’. Regarding claim 12, see rejection of claim 16 under double patenting above, and claim 1 of 125’. Regarding claim 13, see rejection of claim 16 under double patenting above, and claim 1 of 125’. Regarding claim 14, see rejection of claim 5 under double patenting above, and claim 1 of 125’. Regarding claim 15, see rejection of claim 3 under double patenting above, and claim 1 of 125’. Regarding claim 16, see rejection of claim 9 under double patenting above, and claim 1 of 125’. Regarding claim 17, see rejection of claim 16 under double patenting above, and claim 1 of 125’. Regarding claim 18, see rejection of claim 16 under double patenting above, and claim 1 of 125’. Regarding claim 19, see rejection of claim 17 under double patenting above, and claim 1 of 125’. Regarding claim 20, see rejection of claim 17 under double patenting above, and claim 1 of 125’. Claim 1-20 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-20 of copending Application No. 2025/0213777, hereafter 777’ in view of Wang. This is a provisional nonstatutory double patenting rejection. Regarding claim 1, see claim 1 of 777’. The examiner notes the difference between the claims is the concentration and use of benzalkonium salt. Regarding this difference, Wang teaches antimicrobial compositions and is thus considered analogous to the claimed invention. Wang teaches that benzalkonium chloride was used as a cationic surfactants in the composition, where the concentrations ranged from 32μg/mL (para. 0081) to 64μg/mL (para. 0082) depending on what the solution was treating. Per the same citations, benzalkonium chloride was used with chlorhexidine. Therefore, as Benzalkonium chloride may have suitable concentrations of 32 and 64μg/mL in antimicrobial concentrations, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to provide the antimicrobial composition of Rucinski, comprising benzalkonium chloride, with a concentration 32μg/mL or 64 μg/mL, as said concentrations are known to be suitable in the art. As said value is within the claimed range, the prior art reads to the claimed invention. Regarding claim 2, see rejection of claim 1 under double patenting above, and claim 2 of 777’. Regarding claim 3, see rejection of claim 1 under double patenting above, and claim 3 of 777’. Regarding claim 4, see rejection of claim 1 under double patenting above, and claim 4 of 777’. Regarding claim 5, see rejection of claim 1 under double patenting above, and claim 5 of 777’. Regarding claim 6, see rejection of claim 1 under double patenting above, and claim 1 of 777’. Regarding claim 7, see rejection of claim 1 under double patenting above, and claim 1 of 777’. Regarding claim 8, see rejection of claim 1 under double patenting above, and claim 1 of 777’. Regarding claim 9, see rejection of claim 1 under double patenting above, and claim 1 of 777’. Regarding claim 10, see rejection of claim 1 under double patenting above, and claim 10 of 777’. Regarding claim 11, see rejection of claim 16 under double patenting above, and claim 11 of 777’. Regarding claim 12, see rejection of claim 16 under double patenting above, and claim 12 of 777’. Regarding claim 13, see rejection of claim 16 under double patenting above, and claim 13 of 777’. Regarding claim 14, see rejection of claim 5 under double patenting above, and claim 14 of 777’. Regarding claim 15, see rejection of claim 3 under double patenting above, and claim 15 of 777’. Regarding claim 16, see rejection of claim 9 under double patenting above, and claim 16 of 777’. Regarding claim 17, see rejection of claim 16 under double patenting above, and claim 17 of 777’. Regarding claim 18, see rejection of claim 16 under double patenting above, and claim 18 of 777’. Regarding claim 19, see rejection of claim 17 under double patenting above, and claim 19 of 777’. Regarding claim 20, see rejection of claim 17 under double patenting above, and claim 120 of 777’. Claim 1-20 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-20 of copending Application No. 2025/0213542, hereafter 542’ in view of Wang. This is a provisional nonstatutory double patenting rejection. Regarding claim 1, see claim 1 of 542’. The examiner notes the difference between the claims is the concentration and use of benzalkonium salt. Regarding this difference, Wang teaches antimicrobial compositions and is thus considered analogous to the claimed invention. Wang teaches that benzalkonium chloride was used as a cationic surfactants in the composition, where the concentrations ranged from 32μg/mL (para. 0081) to 64μg/mL (para. 0082) depending on what the solution was treating. Per the same citations, benzalkonium chloride was used with chlorhexidine. Therefore, as Benzalkonium chloride may have suitable concentrations of 32 and 64μg/mL in antimicrobial concentrations, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to provide the antimicrobial composition of Rucinski, comprising benzalkonium chloride, with a concentration 32μg/mL or 64 μg/mL, as said concentrations are known to be suitable in the art. As said value is within the claimed range, the prior art reads to the claimed invention. Regarding claim 2, see rejection of claim 1 under double patenting above, and claim 2 of 542’. Regarding claim 3, see rejection of claim 1 under double patenting above, and claim 3 of 542’. Regarding claim 4, see rejection of claim 1 under double patenting above, and claim 4 of 542’. Regarding claim 5, see rejection of claim 1 under double patenting above, and claim 5 of 542’. Regarding claim 6, see rejection of claim 1 under double patenting above, and claim 1 of 542’. Regarding claim 7, see rejection of claim 1 under double patenting above, and claim 1 of 542’. Regarding claim 8, see rejection of claim 1 under double patenting above, and claim 1 of 542’. Regarding claim 9, see rejection of claim 1 under double patenting above, and claim 1 of 542’. Regarding claim 10, see rejection of claim 1 under double patenting above, and claim 10 of 542’. Regarding claim 11, see rejection of claim 16 under double patenting above, and claim 11 of 542’. Regarding claim 12, see rejection of claim 16 under double patenting above, and claim 12 of 542’. Regarding claim 13, see rejection of claim 16 under double patenting above, and claim 13 of 542’. Regarding claim 14, see rejection of claim 5 under double patenting above, and claim 14 of 542’. Regarding claim 15, see rejection of claim 3 under double patenting above, and claim 15 of 542’. Regarding claim 16, see rejection of claim 9 under double patenting above, and claim 1 of 542’. The examiner notes that as the same materials are being used and pH is a property of the solution, the pH of 777’ would be the same as the instant claimed range. Regarding claim 17, see rejection of claim 16 under double patenting above, and claim 16 of 542’. Regarding claim 18, see rejection of claim 16 under double patenting above, and claim 17 of 542’. Regarding claim 19, see rejection of claim 17 under double patenting above, and claim 18 of 542’. Regarding claim 20, see rejection of claim 17 under double patenting above, and claim 19 of 542’. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Matthew Wrubleski whose telephone number is (571)272-1150. The examiner can normally be reached M-F 8:00-4:00 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Rebecca Eisenberg can be reached at 571-270-5879. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW WRUBLESKI/Examiner, Art Unit 3781 /ARIANA ZIMBOUSKI/Primary Examiner, Art Unit 3781
Read full office action

Prosecution Timeline

Dec 29, 2023
Application Filed
Mar 18, 2024
Response after Non-Final Action
Aug 25, 2026
Non-Final Rejection mailed — §103, §112, §DP
Oct 30, 2026
Applicant Interview (Telephonic)
Oct 30, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778788
A LIQUID CAPTURE DEVICE
3y 4m to grant Granted Nov 03, 2026
Patent 12757863
PET PAD INCLUDING EDGE POCKET TO CAPTURE FLUID
3y 6m to grant Granted Oct 13, 2026
Patent 12746320
Medical Waste Collection System For Collecting Medical Waste During A Medical Procedure
3y 6m to grant Granted Sep 29, 2026
Patent 12746321
SUB-ATMOSPHERIC WOUND-CARE SYSTEM
3y 5m to grant Granted Sep 29, 2026
Patent 12727804
SYSTEMS, DEVICES AND METHODS FOR DRAINING AND ANALYZING BODILY FLUIDS AND ASSESSING HEALTH
4y 3m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+60.1%)
3y 0m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 118 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month